Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7536162rdf:typepubmed:Citationlld:pubmed
pubmed-article:7536162lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:7536162lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:7536162lifeskim:mentionsumls-concept:C0021853lld:lifeskim
pubmed-article:7536162lifeskim:mentionsumls-concept:C0243079lld:lifeskim
pubmed-article:7536162lifeskim:mentionsumls-concept:C0597298lld:lifeskim
pubmed-article:7536162lifeskim:mentionsumls-concept:C1533698lld:lifeskim
pubmed-article:7536162lifeskim:mentionsumls-concept:C0282774lld:lifeskim
pubmed-article:7536162lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:7536162pubmed:issue2-3lld:pubmed
pubmed-article:7536162pubmed:dateCreated1995-5-12lld:pubmed
pubmed-article:7536162pubmed:abstractTextThe effects of aminoguanine on the intestinal vascular permeability following endotoxin administration in vivo has been compared to those of the nitric oxide (NO) synthase inhibitor NG-monomethyl-L-arginine (L-NMMA) in the rat. Concurrent administration of aminoguanidine. (12.5-50 mg/kg, s.c.) with endotoxin (E. coli lipopolysaccharide, 3 mg/kg, i.v.), dose dependently increased vascular leakage of radiolabelled albumin in the ileum and colon after 1 h, an effect reversed by the pretreatment with L-arginine (300 mg/kg, s.c.). Aminoguanidine (50 mg/kg, s.c.) also elevated arterial blood pressure over the 1 h investigation period. Similar acute potentiation of endotoxin-provoked vascular injury was observed 1 h following L-NMMA (50 mg/kg s.c.) which also increased blood pressure, indicating the inhibition of constitutive NO synthase. By contrast, administration of aminoguanidine (12.5-50 mg/kg, s.c.) 3 h after endotoxin, at the time of the expression of the inducible NO synthase, reduced the subsequent endotoxin-induced vascular leakage, as did L-NMMA (50 mg/kg). In homogenates of rat ileal or colonic tissue, aminoguanidine inhibited both the constitutive and inducible NO synthase activity showing only 2-fold selectivity for the inducible isoform. Thus, although aminoguanidine inhibits these isoforms of NO synthase, it is not a selective inhibitor of the inducible isoform in the intestinal microvasculature in vivo.lld:pubmed
pubmed-article:7536162pubmed:languageenglld:pubmed
pubmed-article:7536162pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536162pubmed:citationSubsetIMlld:pubmed
pubmed-article:7536162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536162pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536162pubmed:statusMEDLINElld:pubmed
pubmed-article:7536162pubmed:monthJanlld:pubmed
pubmed-article:7536162pubmed:issn0014-2999lld:pubmed
pubmed-article:7536162pubmed:authorpubmed-author:WhittleB JBJlld:pubmed
pubmed-article:7536162pubmed:authorpubmed-author:EvansS MSMlld:pubmed
pubmed-article:7536162pubmed:authorpubmed-author:LaszloFFlld:pubmed
pubmed-article:7536162pubmed:issnTypePrintlld:pubmed
pubmed-article:7536162pubmed:day16lld:pubmed
pubmed-article:7536162pubmed:volume272lld:pubmed
pubmed-article:7536162pubmed:ownerNLMlld:pubmed
pubmed-article:7536162pubmed:authorsCompleteYlld:pubmed
pubmed-article:7536162pubmed:pagination169-75lld:pubmed
pubmed-article:7536162pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:meshHeadingpubmed-meshheading:7536162-...lld:pubmed
pubmed-article:7536162pubmed:year1995lld:pubmed
pubmed-article:7536162pubmed:articleTitleAminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo.lld:pubmed
pubmed-article:7536162pubmed:affiliationWellcome Foundation Ltd., Beckenham, Kent, UK.lld:pubmed
pubmed-article:7536162pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536162lld:pubmed